Loading...
Home2019-03-14T19:25:18+00:00

A Foundation of Clinical Experience.

Linnaeus is a Penn Center for Innovation UPstart company that was founded in 2016 and is based upon discoveries from the Ridky lab at the University of Pennsylvania. We are developing our initial therapies that are supported by a foundation of clinical experience. Being female and having a history of pregnancy are associated with decreased incidence and improved stage specific survival for many cancers, including melanoma, pancreatic ductal adenocarcinoma, non-small cell lung cancer, and colon carcinomas.

See our video here.

Our approach

Applied Knowledge

We believe that if you observe the clinical experience and listen to what it tells us, it will lead to the identification of new therapeutic targets for cancer.

Diverse Team

We have assembled a management and development team with complementary skill sets and differing areas of domain expertise that should allow us to get our drug-candidates into humans as safely and as quickly as possible.

Latest News

Company & industry updates from the Linnaeus team

Linnaeus Therapeutics Announces First Patient Dosed in Its Clinical Trial of LNS8801 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Cancer

Company Commences Phase 2 Study at Multiple Academic Sites in United States Haddonfield NJ, October 13, 2020--Linnaeus Therapeutics, Inc. (Linnaeus), a privately held clinical-stage biopharmaceutical company [...]

Linnaeus Therapeutics Announces Clinical Trial Collaboration Agreement with Merck to Evaluate LNS8801 in Combination with KEYTRUDA in Patients with Advanced Cancer

Linnaeus announced today announced that it has entered into a clinical collaboration agreement with Merck to evaluate the combination of its lead investigational product candidate LNS8801, and Merck’s anti-PD-1 therapy, KEYTRUDA®(pembrolizumab) in patients with [...]

Linnaeus Therapeutics Granted U.S. FDA Fast Track Designation for LNS8801 for the Treatment of Patients with Metastatic or Unresectable Melanoma Who Have Progressed on Anti–PD-1/L1 Therapy

Linnaeus Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for LNS8801 for the treatment of patients with metastatic or unresectable melanoma who have progressed on or [...]

Read latest news

We Listen to the Clinical Experience

We allow it to inform the science that drives the development of new treatments to treat cancer.

Contact Us